Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.53 |
| ▸ | CNR1 | P21554 | 10/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC6A19 | Q695T7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016626 | 1.00 | CNR2 (0.53) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL19629155 | 0.91 | CNR2 (0.42) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL1099502 | 0.83 | — | — | |
| SCHEMBL4138284 | 0.83 | — | — | |
| SCHEMBL11103679 | 0.82 | CNR2 (0.53) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL11103678 | 0.82 | CNR2 (0.53) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL2535335 | 0.80 | SLC6A19 (0.44) | SLC6A19ALDH1A1 | |
| SCHEMBL1395660 | 0.80 | SLC6A19 (0.44) | SLC6A19ALDH1A1 | |
| SCHEMBL1395636 | 0.80 | SLC6A19 (0.44) | SLC6A19ALDH1A1 | |
| SCHEMBL9531499 | 0.79 | CNR2 (0.47) | CNR2CNR1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012036383-A3 | USE OF A PROTEIN TYROSINE KINASE INHIBITOR FOR INDUCING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARDIOGENIC CELLS | 파미셀 주식회사 (KR) | 2012-05-10 | — | — | WO | disclosed |
| EP-1927587-B1 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INT FLAVORS & FRAGRANCES INC (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-1927587-B1 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INT FLAVORS & FRAGRANCES INC (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-1927587-A2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES, INC. (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1927587-A2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES, INC. (US) | 2008-06-04 | — | — | EP | disclosed |
| US-7329767-B2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329767-B2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329767-B2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050075368-A1 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC.WW | 2005-04-07 | — | — | US | disclosed |
| EP-1520850-A2 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2005-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075368-A1 | Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof | TAS2R41, TAS2R42, TAS2R14 | CNR2 1265/4885CNR1 1556/4885PPARG 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.